References

Management of muscle-invasive urothelial cancer and the emerging role of immunotherapy in advanced urothelial cancer

10.1016/j.mayocp.2017.07.010 · 2017 · External reference

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2021 · External reference

Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline

10.1016/j.juro.2016.06.049 · 2016 · External reference

Systematic review of the therapeutic efficacy of bladder-preserving treatments for non-muscle-invasive bladder cancer following intravesical Bacillus Calmette-Guerin

10.1016/j.eururo.2020.02.012 · 2020 · External reference

High-risk non-muscle-invasive bladder cancer-therapy options during intravesical BCG shortage

10.1007/s11934-016-0625-z · 2016 · External reference

Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival

10.1186/s12885-021-08418-y · 2021 · External reference

Treatment outcomes of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world evidence (RWE) studies: systematic literature review (SLR)

10.2147/ceor.s341896 · 2022 · External reference

Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways

10.1016/j.urolonc.2009.07.025 · 2011 · External reference

EV-302: updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV + P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC)

10.1200/jco.2025.43.5_suppl.664 · 2025 · External reference

LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase III KEYNOTE-905 study

10.1016/j.annonc.2025.09.124 · 2025 · External reference

Defining the role of integrin αvβ6 in cancer

10.2174/138945009788680374 · 2009 · External reference

Integrin alpha v beta 6 (αvβ6) and its implications in cancer treatment

10.3390/ijms232012346 · 2022 · External reference

Integrins in cancer: biological implications and therapeutic opportunities

10.1038/nrc2748 · 2010 · External reference

Integrins as therapeutic targets

10.1016/j.tips.2012.04.002 · 2012 · External reference

Every step of the way: integrins in cancer progression and metastasis

10.1038/s41568-018-0038-z · 2018 · External reference

Alpha-v integrins as therapeutic targets in oncology

10.1080/07357900701522638 · 2007 · External reference

The integrins

10.1186/gb-2007-8-5-215 · 2007 · External reference

Function and interactions of integrins

10.1007/s004410100417 · 2001 · External reference

β6 -integrin serves as a novel serum tumor marker for colorectal carcinoma

10.1002/ijc.32137 · 2019 · External reference

A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer

10.1158/0008-5472.can-07-0245 · 2007 · External reference

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial

10.1093/annonc/mdu474 · 2015 · External reference

Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival

10.1002/path.2168 · 2007 · External reference

Integrin alphanvbeta6 acts as a prognostic indicator in gastric carcinoma

10.1016/j.clon.2007.09.008 · 2008 · External reference

SGN-CD228A is an investigational CD228-directed antibody-drug conjugate with potent antitumor activity across a wide spectrum of preclinical solid tumor models

10.1158/1535-7163.mct-22-0401 · 2023 · External reference

Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint

10.1016/j.devcel.2004.09.002 · 2004 · External reference

Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?

10.1038/bjc.2017.367 · 2017 · External reference

SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models

10.1136/jitc-2023-007572 · 2023 · External reference

Brentuximab vedotin-driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity

10.1158/1535-7163.mct-23-0118 · 2024 · External reference

Abstract LB246: enfortumab vedotin, a nectin-4-directed antibody-drug conjugate, demonstrates compelling antitumor activity in non-muscle invasive bladder cancer models which predicts minimal systemic exposure when administered by intravesical instillation in patients

10.1158/1538-7445.am2023-lb246 · 2023 · External reference

Rethinking the path to bladder cancer staging: can magnetic resonance imaging speed up time to receipt of therapy in patients with muscle-invasive bladder cancer?

10.1200/jco-24-02482 · 2025 · External reference

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

10.1038/nbt.3212 · 2015 · External reference

SGN-B6A: a new vedotin antibody–drug conjugate directed to integrin beta-6 for multiple carcinoma indications

10.1158/1535-7163.mct-22-0817 · 2023 · External reference

Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs

10.1038/nmeth.3853 · 2016 · External reference

Unresolved reference

2005 · External reference

The design, analysis and application of mouse clinical trials in oncology drug development

10.1186/s12885-019-5907-7 · 2019 · External reference

Intravesical therapy with the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab is well tolerated and shows encouraging preliminary efficacy in patients with high-risk NMIBC (CATUNIBLA phase I trial)

10.1200/jco.2022.40.16_suppl.e16555 · 2022 · External reference

Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma

10.3389/fphar.2024.1326296 · 2024 · External reference

Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma

10.1080/14712598.2021.1929168 · 2021 · External reference

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

10.1136/jitc-2019-000337 · 2020 · External reference

Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium

10.1016/j.ymthe.2004.07.002 · 2004 · External reference

Optimizing absorption for intranasal delivery of drugs targeting the central nervous system using alkylsaccharide permeation enhancers

10.3390/pharmaceutics15082119 · 2023 · External reference

Improvement of intranasal drug delivery with Intravail® alkylsaccharide excipient as a mucosal absorption enhancer aiding in the treatment of conditions of the central nervous system

10.1007/s40268-021-00360-5 · 2021 · External reference

Preclinical and pharmacological studies of AG284, a soluble HLA-DR2:myelin basic protein peptide complex for the treatment of multiple sclerosis

10.1111/j.1527-3458.1998.tb00066.x · 1998 · External reference

Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer

10.1093/annonc/mdw678 · 2017 · External reference

Proliferation and regeneration of the healthy human urothelium: a multi-scale simulation approach with 16 hypotheses of cell differentiation

10.1371/journal.pone.0325132 · 2025 · External reference

Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody–drug conjugate (ADC), and pembrolizumab combination therapy: initial results from an ongoing phase 1 study (SGNB6A-001)

10.1200/jco.2025.43.16_suppl.3010 · 2025 · External reference

Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center’s real-world study

10.3389/fphar.2023.1230395 · 2023 · External reference

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

10.1016/s1470-2045(21)00147-9 · 2021 · External reference

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

10.1038/s41591-025-03738-z · 2025 · External reference

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

10.1016/s0140-6736(25)01897-5 · 2025 · External reference

The PRIDE database at 20 years: 2025 update

10.1093/nar/gkae1011 · 2025 · External reference